Paclitaxel-Induced Pneumonitis in Trinidad: A Case Report

Paclitaxel-induced pneumonitis (PIP) is an immune-mediated disease resulting from a delayed hypersensitivity reaction (type IV) to paclitaxel, an anti-microtubule chemotherapeutic drug commonly used to treat breast cancer in both neoadjuvant and adjuvant settings. PIP is diagnosed by exclusion utili...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-07, Vol.14 (7)
Main Authors: Mohan, Nishtha, Dalip, Dominic, Rampersad, Fidel S, Jaggernauth, Shiva
Format: Article
Language:English
Subjects:
Allergy/Immunology
Antibiotics
Breast cancer
Cancer therapies
Carbon monoxide
Case reports
Chemotherapy
Drug dosages
Dyspnea
Gastroesophageal reflux
Laboratories
Lavage
Lungs
Oncology
Patients
Pulmonary embolisms
Pulmonology
Steroids
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Paclitaxel-induced pneumonitis (PIP) is an immune-mediated disease resulting from a delayed hypersensitivity reaction (type IV) to paclitaxel, an anti-microtubule chemotherapeutic drug commonly used to treat breast cancer in both neoadjuvant and adjuvant settings. PIP is diagnosed by exclusion utilizing laboratory work-up, imaging, biopsy studies, and results of antibiotic therapy because there is no single diagnostic test. Ground-glass opacifications on CT, coupled with minimal restrictive disturbance with decreased diffusion on pulmonary function tests (PFTs), negative bronchoalveolar lavage (BAL), and bronchoscopy cultures, may assist physicians in diagnosing paclitaxel-induced pneumonitis. In this report, we describe a case of PIP present in Trinidad, West Indies, which has not been described previously in this region.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.26613